
AbCellera Biologics Inc.: updates and filings
Price
$11.02
November 18, 2026Market cap $3.6B
What Ploutos Investor adds for AbCellera Biologics
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 8, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 13, 2026Material agreement entered, other material eventsForm8-K
- Aug 10, 2026Regulation FD disclosureForm8-K
- Aug 7, 2026Other material eventsForm8-K
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 29, 2026Other material eventsForm8-K
- Jul 6, 2026Officer or director changeForm8-K
- Jun 17, 2026Other material eventsForm8-K
- Jun 12, 2026Shareholder voteForm8-K
- Jun 5, 2026Officer or director changeForm8-K
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 11, 2026Results of operations, Regulation FD disclosureForm8-K
- May 7, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 29, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Annual meeting proxy statementFormDEF 14A
- Feb 24, 2026Shares registered for employeesFormS-8
- Feb 24, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 24, 2026Results of operations, Regulation FD disclosureForm8-K
- Jan 14, 2026Regulation FD disclosureForm8-K
- Dec 18, 2025Regulation FD disclosureForm8-K
- Nov 28, 2025Change of auditorForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 13, 2026 | 8-K | Material agreement entered, other material events | Document |
| Aug 10, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 7, 2026 | 8-K | Other material events | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 29, 2026 | 8-K | Other material events | Document |
| Jul 6, 2026 | 8-K | Officer or director change | Document |
| Jun 17, 2026 | 8-K | Other material events | Document |
| Jun 12, 2026 | 8-K | Shareholder vote | Document |
| Jun 5, 2026 | 8-K | Officer or director change | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 11, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| May 7, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Feb 24, 2026 | S-8 | Shares registered for employees | Document |
| Feb 24, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 24, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jan 14, 2026 | 8-K | Regulation FD disclosure | Document |
| Dec 18, 2025 | 8-K | Regulation FD disclosure | Document |
| Nov 28, 2025 | 8-K | Change of auditor | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 6, 2017.
The full analysis
What do AbCellera Biologics's filings show?
The filings are where every one of AbCellera Biologics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.